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Hepatotropic viruses such as hepatitis C virus cause life-threatening chronic liver infections in millions of 
people worldwide. Targeted in vivo antigen-delivery to cross-presenting dendritic cells (DCs) has proven 
to be extraordinarily efficient in stimulating antigen-specific T cell responses. To determine whether 
this approach would as well be suitable to induce local antiviral effector T cells in the liver we compared 
different vaccine formulations based on either the targeting of DEC-205 or TLR2/6 on cross-presenting 
DCs or formulations not involving in vivo DC targeting. As read-outs we used in vivo hepatotropic 
adenovirus challenge, histology and automated multidimensional fluorescence microscopy (MELC). 
We show that targeted in vivo antigen delivery to cross-presenting DCs is highly effective in inducing 
antiviral CTLs capable of eliminating virus-infected hepatocytes, while control vaccine formulation not 
involving DC targeting failed to induce immunity against hepatotropic virus. Moreover, we observed 
distinct patterns of CD8+ T cell interaction with virus-infected and apoptotic hepatocytes in the two 
DC-targeting groups suggesting that the different vaccine formulations may stimulate distinct types of 
effector functions. Our findings represent an important step toward the future development of vaccines 
against hepatotropic viruses and the treatment of patients with hepatic virus infection after liver 
transplantation to avoid reinfection.
The liver is permanently exposed to a plethora of antigens and microbial products with potentially 
immune-stimulatory capacity. The predominantly tolerogenic microenvironment of the liver usually prevents 
the induction of immunity to these innocuous antigens while at the same time it favours the establishment of per-
sistent liver infection1,2. Next to other hepatotropic viruses, such as cytomegalovirus (CMV) or hepatitis B virus 
(HBV), a clinically highly relevant example for pathogens capable of establishing life-threatening chronic infec-
tions in the liver is the hepatitis C virus (HCV)3. Despite extensive research since the discovery of HCV in 19894, 
an effective vaccine is still not available5.
1Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany & Infection 
Immunology Group, Institute of Medical Microbiology, Infection Control and Prevention, Medical Faculty of the 
Otto-von-Guericke University Magdeburg, Magdeburg, Germany. 2Department of Vaccinology and Applied 
Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. 3Intravital Microscopy in Infection 
and Immunity, Institute for Molecular and Clinical Immunology, Medical Faculty of the Otto-von-Guericke University 
Magdeburg, Magdeburg, Germany. 4Department of Molecular Immunology, Helmholtz Centre for Infection 
Research, Braunschweig, Germany. 5Institute of Molecular Immunology, Technische Universität München, Germany. 
6Department of Veterinary Medicine, Institute of Veterinary Pathology, Free University Berlin, Berlin, Germany. 
7Institute of Molecular Medicine and Experimental Immunology, Universität Bonn, Germany. †Present address: 
Institute for Laboratory Animal Science, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, 
Germany. ‡Present address: Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and 
Clinical Infection Research, 30625 Hannover, Feodor-Lynen-Strasse 7, Germany. Correspondence and requests for 
materials should be addressed to D.B. (email: dunja.bruder@med.ovgu.de)
Received: 08 December 2015
Accepted: 02 February 2017
Published: 07 March 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:43985 | DOI: 10.1038/srep43985
Dendritic cells (DCs) represent optimal targets for designing effective vaccines6. CD8α + DCs are unique 
with respect to their capacity to effectively cross-present exogenous antigens on MHC-I molecules to induce 
cytotoxic T cells (CTLs) in addition to Th1 responses7,8. Accordingly, CD8α + DCs play a key role in establishing 
antiviral immunity9,10. Increasing knowledge regarding the characteristics of pattern recognition receptor (PRR) 
expression by different DC subsets has set the basis for a directed targeting of antigen in vivo by means of ligands 
or antibodies specific for the respective PRRs expressed on DCs. In this context, particularly Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs) gained importance11. For instance, the TLR2/6 heterodimer agonist 
S-[2,3-bispalmitoyloxy-(2R)-propyl]-R-cysteinyl-amido-mono-methoxyl polyethylene glycol (BPPcysMPEG), 
a synthetic derivative of the macrophage-activating lipopeptide (MALP-2), effectively targets cross-presenting 
CD8α + DCs. Importantly, co-administration of BPPcysMPEG together with soluble ovalbumin (OVA) 
(OVA + BPPcysMPEG) resulted in the induction of OVA-specific CTLs12. Interestingly, BPPcysOVAMPEG, a 
compound consisting of the immunodominant OVA peptides chemically linked to BPPcysMPEG and therefore 
specifically delivered to TLR2/6 positive DCs, was even more effective at inducing OVA-specific CTLs12.
Next to the TLR2/6 heterodimer, CD8α + DCs express high levels of the CLR family endocytosis receptor 
DEC-20513. Importantly, receptor-mediated antigen uptake by CD8α + DCs via DEC-205 results in extraordinar-
ily effective antigen cross-presentation to CD8+ T cells14–18. Steinman and colleagues demonstrated that in vivo 
targeting of antigen to cross-presenting DCs by means of DEC-205-directed antibody-antigen conjugates together 
with the appropriate adjuvants resulted in a potent induction of specific T cell responses19,20. Follow up studies 
with viral14,16,17,21, bacterial22,23 and tumour antigens24,25 proved DEC-205-mediated antigen delivery to CD8α + 
DCs to elicit protective CD4+ and CD8+ T effector cells. However, no study so far addressed whether antigen 
delivery to cross-presenting CD8α + DCs is able to induce effector T cell responses and antiviral immunity in the 
liver. To improve vaccination efficacy against hepatotropic viruses, we compared different vaccine formulations 
regarding their potency to induce antiviral effector T cell responses in the liver. This included targeted antigen 
delivery to cross-presenting DCs by α DEC-205 conjugated to the OVA protein (α DEC-205/OVA adjuvanted with 
Poly(I:C)/CpG) and the less well studied BPPcysOVAMPEG containing the two immunodominant MHC-I and 
-II OVA peptides. To assess whether antigen targeting to DCs would be required for inducing antiviral effector T 
cells in the liver, another group that received OVA co-administered with BPPcysMPEG (OVA + BPPcysMPEG) 
and thus not involving targeted antigen delivery to DCs was included. We show that only immunization with the 
DC targeting formulation α DEC-205/OVA and BPPcysOVAMPEG but not OVA + BPPcysMPEG vaccination 
induced CD8+ effector T cells capable of eliminating virus infected hepatocytes. Thus, we conclude that targeted 
in vivo antigen delivery to cross-presenting DCs represents a promising approach for the induction of antiviral 
immunity in the liver with potential implications for the development of vaccines against hepatotropic viruses.
Results
Targeting antigen to DCs induces humoral immunity. We first compared the OVA-specific humoral 
immune response after immunization with either α DEC-205/OVA adjuvanted with Poly(I:C) and CpG (α DEC-
205/OVA + Poly(I:C)/CpG; for simplification termed α DEC-205/OVA), BPPcysOVAMPEG or, in addition to the 
two DC targeting approaches, BPPcysMPEG co-administered together with soluble OVA (OVA + BPPcysMPEG). 
As controls we included α DEC-205 and OVA alone, both adjuvanted with Poly(I:C) and CpG as well as 
BPPcysMPEG alone, OVA peptides alone, and OVA peptides adjuvanted with BPPcysMPEG.
Already after two vaccinations with α DEC-205/OVA, we observed a strong OVA-specific IgG response 
(Fig.  1A) that was significantly increased in comparison to both the OVA + BPPcysMPEG and the 
OVA + Poly(I:C)/CpG groups at this time (Fig. 1B). Mice vaccinated with the novel antigen targeting system 
BPPcysOVAMPEG initially exhibited a weaker IgG response, which was however strongly enhanced following 
the third boost (Fig. 1A,C).
We next compared OVA-specific IgG1 and IgG2c titres which represent the main IgG isotypes stimu-
lated by Th2 and Th1 cells, respectively26. Vaccination with either α DEC-205/OVA, OVA + Poly(I:C)/CpG or 
BPPcysOVAMPEG induced a rather balanced IgG1/IgG2c ratio, whereas OVA + BPPcysMPEG induced substan-
tially higher IgG1 than IgG2c titres, pointing towards a more Th2-dominated immune response (Fig. 1D). As 
expected, neither the injection of the adjuvant BPPcysMPEG alone, nor the vaccination with the immunodomi-
nant CD4+ and CD8+ OVA peptides without adjuvant did induce humoral immunity. Moreover, peptide target-
ing to DCs by means of vaccination with BPPcysOVAMPEG was superior in inducing antibody responses than 
vaccination with soluble peptides adjuvanted with BPPcysMPEG (Supplementary Fig. S1A–C).
Induction of CTLs following αDEC-205/OVA and BPPcysOVAMPEG immunization. To further 
characterize the type of T cell response induced with the different vaccine formulations, OVA-specific IL-4- and 
IFNγ -secreting T cells were evaluated by ex vivo stimulation of splenocytes from immunized mice with the dom-
inant OVA MHC-I and -II peptides. As expected, due to the exclusive selection towards these epitopes when 
immunizing with BPPcysOVAMPEG, the highest number of cytokine producing T cells was observed in this 
group (Fig. 2A–C). BPPcysOVAMPEG vaccination induced increased numbers of IL-4-producing Th2 cells com-
pared to the α DEC-205/OVA and OVA + Poly(I:C)/CpG immunized groups (Fig. 2A). Compared to the vaccine 
formulations lacking direct antigen targeting to DCs, BPPcysOVAMPEG, and to a lesser extent α DEC-205/OVA 
immunization, at the same time showed the strongest potential to induce IFNγ -producing T cells (Fig. 2B,C). Of 
note, the adjuvant BPPcysMPEG alone or vaccination with non-adjuvanted immunodominant OVA peptides did 
not induce IFNγ -producing T cells. Furthermore, peptide targeting to DCs using the BPPcyOVAMPEG formula-
tion induced significantly more IFNγ -producing T cells than vaccination of mice using peptides adjuvanted with 
BPPcysMPEG (Supplementary Fig. S1D–G).
Since IFNγ -producing CTLs are important for virus clearance from the liver27, we evaluated OVA-specific 
CTL activity in vaccinated mice. Immunization with α DEC-205/OVA or BPPcysOVAMPEG induced a robust 
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OVA-specific CTL response already after the first immunization (Fig. 2D). Despite the fact that IFNγ -producing 
CD8+ T cells were also induced in OVA + BPPcysMPEG immunized mice (Fig. 2C) no lysis of target cells was 
detectable in this group (Fig. 2D). Thus, while antigen delivery to DCs by targeting DEC-205 resulted in a rather 
weak and balanced Th1 (IFNγ ) and Th2 (IL-4) cell response, it was highly effective in generating antigen-specific 
CTLs. Similarly, BPPcysOVAMPEG-mediated antigen targeting to TLR2/6 induced balanced Th1/Th2 T helper 
and robust OVA-specific CTL responses.
Targeted antigen delivery to DCs induces IFNγ-producing memory CD8+ T cells in the liver. To 
test whether CTLs induced by antigen delivery to DCs can effectively recognize and eliminate virus infected 
hepatocytes, a hepatotropic adenovirus challenge model was utilized (Fig. 3A). Immunized mice were infected 
with a recombinant adenovirus (AdOVA-GFP-luc) leading to the MHC-I presentation of the OVA CD8257–264 
peptide on infected hepatocytes. Furthermore, AdOVA-GFP-luc infected cells express EGFP (enhanced green 
fluorescent protein) and luciferase, allowing the quantification of the infection (Fig. 3A)28. While infection of 
Figure 1. Antigen targeting to DCs induces IgG responses of distinct kinetics and subtype distribution. 
Mice (n = 5) were immunized on days 0, 14 and 28 with α DEC-205/OVA + Poly(I:C)/CpG, α DEC-
205 + Poly(I:C)/CpG, BPPcysOVAMPEG, OVA + Poly(I:C)/CpG, OVA + BPPcysMPEG or PBS followed 
by determining OVA-specific serum IgG titres. Results are compiled from three independent experiments. 
(A) Kinetic of OVA-specific serum IgG titres. (B) OVA-specific IgG titre on day 27 and (C) day 42. Statistics: 
one-way Anova (mean ± SD) (**p < 0.01). (D) OVA-specific serum IgG1 and IgG2c titres on day 42. Statistics: 
non-parametric Mann Whitney test comparing the IgG1 to IgG2c subclasses within the groups (mean ± SD) 
(*p ≤ 0.015, ***p < 0.0001).
www.nature.com/scientificreports/
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Figure 2. Induction of IFNγ-producing CTLs following αDEC-205/OVA and BPPcysOVAMPEG 
immunization. Mice were immunized days 0, 14 and 28 with α DEC-205/OVA + Poly(I:C)/CpG, α DEC-
205 + Poly(I:C)/CpG, BPPcysOVAMPEG, OVA + Poly(I:C)/CpG, OVA + BPPcysMPEG or PBS. IL-4 (A) or 
IFNγ (B), (C) spot forming units/106 splenocytes following stimulation with the indicated OVA-peptides on day 
42. Bars represent the mean ± SEM (n = 5, triplicates from pooled animals) of three independent experiments 
(**p < 0.01, ***p < 0.0001). (D) In vivo cytotoxicity assay: mice (n = 3) were immunized once, twice or thrice. 
Histograms: CFSE+ splenocytes in one representative mouse per group and per point in time. Bars: percentage 
of specific lysis as mean ± SEM. Statistics: one-way Anova (*p < 0.05, **p < 0.01, ***p ≤ 0.0007).
www.nature.com/scientificreports/
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α DEC-205 mock-immunized mice with AdOVA-GFP-luc did not lead to an accumulation of CD44highCD8+ T 
cells in the liver, an accumulation of intrahepatic CD44highCD8+ T cells was detectable in all other experimental 
groups following AdOVA-GFP-luc infection (Fig. 3B).
The release of IFNγ by CTLs has been shown to mediate non-cytolytic clearance of infected hepatocytes and 
IFNγ per se directly inhibits viral replication in the liver29,30. While hardly any IFNγ production was detecta-
ble in the hepatic CD44-CD8+ T cells (Fig. 3C), the AdOVA-GFP-luc challenge resulted in a nearly two-fold 
increase of the proportion of IFNγ -producing CD44highCD8+ T cells in the OVA + BPPcysMPEG (11.3%) and 
Figure 3. Antigen targeting to DCs induces accumulation of IFNγ+CD8+ T cells in the liver. (A) Experimental 
setup: adenovirus challenge assay. Mice (n = 5) were immunized on days 0, 14 and 28 either with α DEC-205/
OVA + Poly(I:C)/CpG, α DEC-205 + Poly(I:C)/CpG, BPPcysOVAMPEG or OVA + BPPcysMPEG and challenged 
with AdOVA-GFP-luc or Ad-GFP-luc on day 48. (B) 4 days after infection, liver lymphocytes were analysed by 
flow cytometry. Representative density plots show CD8+ liver T lymphocytes with the percentages of CD44+ and 
CD44− expression. Bars represent the proportions of CD44highCD8+ cells. (C) Overlays show IFNγ -producing 
CD44−CD8+ (grey) and CD44highCD8+ (blue) liver T cells. Bars display the percentages of IFNγ -producing 
CD44−CD8+ (left) and CD44highCD8+ (right) cells.
www.nature.com/scientificreports/
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BPPcysOVAMPEG (14.4%) immunized animals. Strikingly, α DEC-205/OVA vaccination resulted in an excep-
tionally strong accumulation of IFNγ -producing CD44highCD8+ effector memory T cells (27.6%) in the liver 
following AdOVA-GFP-luc infection (Fig. 3C).
Presence of IFNγ+CD44highCD8+ effector T cells in the liver correlates with hepatitis devel-
opment following AdOVA-GFP-luc challenge. We next asked whether the IFNγ -producing effector 
memory CD8+ T cells in the liver would respond to virus-expressed antigen on hepatocytes. While Ad-GFP-luc 
control infection induced only marginal hepatocellular cell death or cellular infiltrations (Fig. 4A), infection of 
all OVA-immunized groups with AdOVA-GFP-luc led to drastic histological lesions in the liver, hepatocellular 
cell death and marked infiltration of lymphocytes and macrophages into the tissue (Fig. 4A–C). Since histological 
scoring revealed a trend towards an enhanced immunopathology in the liver of α DEC-205/OVA immunized and 
AdOVA-GFP-luc infected mice compared to the BPPcysOVAMPEG group, we further elucidated whether α DEC-
205/OVA and BPPcysOVAMPEG vaccination would result in distinct immune cell recruitment following viral 
Figure 4. Adenovirus challenge induces antigen-specific liver pathology. Mice (n = 3) were immunized 
on days 0, 14 and 28 either with α DEC-205/OVA + Poly(I:C)/CpG, α DEC-205 + Poly(I:C)/CpG, 
BPPcysOVAMPEG or OVA + BPPcysMPEG and three weeks after the last immunization they were infected 
with AdOVA-GFP-luc or Ad-GFP-luc. On day 4 after adenovirus infection, livers were harvested for histological 
examination. (A) Macrophages (arrow), lymphocytes (arrowhead) and necrotic hepatocytes (*) are indicated 
(scale bar = 100 μ m). (B) Necrosis and (C) tissue inflammation was assessed. 5 mice per group were analysed. 
Mean of scattered dot plots are represented.
www.nature.com/scientificreports/
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infection. However, automated multidimensional fluorescent microscopy (MELC) on liver sections revealed no 
significant differences in the hepatic composition of leukocytes, macrophages, neutrophils, NK cells, B cells and 
T cell subsets among the groups (Fig. 5A,B and Supplementary Fig. S2). Altogether, the observed type of immu-
nopathology in α DEC-205/OVA and BPPcysOVAMPEG immunized mice was indicative for acute hepatitis as 
a consequence of the immune-mediated clearance of virus infected hepatocytes suggesting that antigen-specific 
CTLs present in the liver following vaccination accounted for the hepatocyte damage.
Vaccination with αDEC-205/OVA and BPPcysOVAMPEG results in effective antigen-specific 
virus clearance in the liver. To further substantiate the cytolytic function of CTLs, serum concentrations 
of alanine transaminase (ALT) were determined in vaccinated and adenovirus-challenged animals. As expected, 
infection with the Ad-GFP-luc control virus did not affect serum ALT levels in any of the experimental groups 
(Fig. 6A). Strikingly, in α DEC-205/OVA as well as in BPPcysOVAMPEG immunized mice we observed a dra-
matic and comparably high increase of the serum ALT level (~950 U/l and ~770 U/I, respectively) indicating 
massive CTL-mediated killing of AdOVA-GFP-luc infected hepatocytes (Fig. 6A). Significantly lower ALT con-
centrations (~330 U/l) were measured in OVA + BPPcysMPEG immunized mice which is in line with lower 
abundance of IFNγ -producing memory CD8+ T cells (Fig. 3).
To further confirm specific killing of AdOVA-GFP-luc infected hepatocytes, virus clearance was examined by 
assessing luciferase expression in liver tissue. As expected, strong luciferase activity was detectable in the liver of 
all mice infected with the control Ad-GFP-luc virus (Fig. 6B). In contrast, luciferase activity in the livers of immu-
nized and AdOVA-GFP-luc infected mice was significantly reduced in α DEC-205/OVA and BPPcysOVAMPEG 
vaccinated mice in comparison to both OVA + BPPcysMPEG and α DEC-205 + Poly(I:C)/CpG mock-immunized 
animals (Fig. 6B). Taken together, our results clearly demonstrated that antigen targeting to cross-presenting DCs 
by either α DEC-205/OVA or BPPcysOVAMPEG is highly effective at inducing effector T cells capable of recog-
nizing and eliminating virus infected hepatocytes.
Vaccination with αDEC-205/OVA and BPPcysOVAMPEG induces distinct patterns of CD8+ T cell 
interaction with virus infected and apoptotic hepatocytes. In order to gain first indication regarding 
the underlying mechanisms for the elimination of infected hepatocytes we analysed liver sections of α DEC-205/
OVA and BPPcysOVAMPEG immunized and AdOVA-GFP-luc infected mice for potential differences in the dis-
tance of CD8+ T cells to virus infected hepatocytes. While we did neither observe significant differences in the 
number of virus infected hepatocytes, nor in the number of hepatocytes staining positive for active caspase-3 
(Fig. 5C,D) or in the frequency of CD8+ T cells being in loose contact with infected hepatocytes (> 22 μ m 
distance, Fig. 5E), we indeed observed significantly fewer CD8+ T cells being in direct contact (< 9 μ m) to 
AdOVA-GFP-luc infected hepatocytes in α DEC-205/OVA immunized mice compared to the BPPcysOVAMPEG 
immunized group (Fig. 5E). Strikingly, despite lower abundance of CD8+ T cells being in intimate contact with 
virus infected cells, substantially more of them were found to be closely associated with active caspase-3 and 
thus apoptotic cells in the liver of α DEC-205/OVA immunized mice (Fig. 5E). Together with the observation 
that compared to BPPcysOVAMPEG vaccination α DEC-205/OVA immunization resulted in the accumulation 
of significantly higher frequency of IFNγ +CD44highCD8+ effector T cells in virus infected livers (Fig. 3C) these 
data may indicate that the two different DC-targeting formulations may indeed stimulate distinct types of effector 
functions being active during virus elimination from the liver.
Discussion
We show here that in vivo antigen delivery to CD8α + cross-presenting DCs is highly effective in inducing anti-
viral immunity in the liver. BPPcysOVAMPEG vaccination, which was included as a novel antigen targeting 
system, exhibited outstanding properties in inducing high antibody titres (Fig. 1), Th1 and Th2 cells, as well 
as CTLs (Fig. 2) that effectively cleared virus infected hepatocytes (Fig. 6). Although not reaching statistical 
significance compared to α DEC-205/OVA vaccination, this approach tended to promote a more robust viral 
clearance, as well as slightly less pronounced hepatocellular cell death and pro-inflammatory effect. The value of 
TLR agonist-antigen conjugates for inducing Th1 and CD8+ T cell responses are clearly underscored by our new 
data and previous studies31,32. However, for clinical application such conjugates will need to be tailored to match 
different HLA alleles and rapidly mutating viruses (e.g. HCV)33. It could be possible to exploit chemical groups 
of BPPcysMPEG to generate conjugates with more complex antigens or to engineer universal docking systems 
enabling non-covalent binding, such as those used in the past for antibodies34.
Prajeeth et al. have shown that BPPcysMPEG-mediated activation of CD8+ DCs led to effective cross-priming 
against co-administered antigen resulting in CTL responses in the spleen12. While we detected small numbers of 
CD44+CD8+ memory T cells in the liver of OVA + BPPcysMPEG immunized mice following AdOVA-GFP-luc 
infection (Fig. 3), these cells did not exert effector functions (Figs 2 and 6). These discrepancies may be due to 
differences in the antigen concentration used (3 mg vs. 7 μ g)12. However, we have no explanation yet why the 
memory T cells present in the liver of OVA + BPPcysMPEG immunized mice did not exhibit cytotoxic function. 
Strikingly, despite the lack of viral eradication in the OVA + BPPcysMPEG vaccinated group, these mice dis-
played marked immunopathology and elevated ALT levels following AdOVA-GFP-luc infection. We may specu-
late that, although being functionally impaired in terms of cytotoxicity, antigen-specific recognition of the virus 
by IFNγ +CD44+CD8+ T cells results in cytokine release followed by innate immune activation and immune cell 
recruitment that finally result in hepatic cell death and inflammation independent of CTL mediated killing.
Immunization with α DEC-205/OVA induced a robust CTL response (Fig. 2), which resulted in effective viral 
clearance in the liver (Fig. 6). Our data are well in line with a previous study demonstrating that vaccination with 
α DEC-205/OVA induces CD8+ T cells capable to protect against tumour or virus challenge14. Similar results were 
obtained by targeting tumour24,25 or viral antigens21,35 to DEC-205+ DCs. Next to the CTL response induced in 
www.nature.com/scientificreports/
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Figure 5. Distinct CD8+ T cell/hepatocyte interaction pattern in virus infected livers of αDEC-205/OVA 
and BPPcysOVAMPEG immunized mice. Mice (n = 3–4) were immunized on days 0, 14 and 28 either with 
αDEC-205/OVA + Poly(I:C)/CpG or BPPcysOVAMPEG and challenged with AdOVA-GFP-luc or Ad-GFP-luc 
control. 4 days after adenovirus infection, liver lobes were harvested for MELC analysis. (A,B) Tissue sections 
of immunized and AdOVA-GFP-luc infected mice. Scale bars = 100 μ m. Graph: quantification of immune cell 
subsets as percentages of all detected cells. (A) Immune cell infiltration: black = actin, liver structure; green = GFP-
tagged virus (AdOVA-GFP-luc); orange = leukocytes (CD45); purple = macrophages (F4/80); blue = neutrophils 
(PMN) (CD11bhigh); cyan = natural killer cells (NK1.1). (B) Lymphocytes: light yellow = B cells (CD45R+); 
red = CTL (CD8); light blue = CD4 T cell. (C) Interaction of virus infected cells with CTLs: green = GFP-tagged 
virus (AdOVA-GFP-luc); yellow = apoptotic cell (active caspase-3+); red = CTL (CD8); white = liver structure 
(actin + CD138); blue/green = nuclei (propidiumiodid); blue = eomes; purple = macrophages (F4/80). Scale 
bars = 100 μ m or 50 μ m (zoom). (D) Quantification of virus infected cells or active caspase-3+ cells: n = 3 with 2–4 
fields of view were measured per animal. (E) Localization analysis of CD8+ T cells in relation to virus infected cells 
and apoptotic cells. Upper graph: percentages of CD8+ cells in direct (< 9 μ m) or loose contact (> 22 μ m) to virus 
infected cells. Lower graph: percentages of CD8+ cells in direct contact (< 9 μ m) to virus infected cells which are 
close (< 22 μ m) to cells expressing active caspapse-3. Statistics: paired, two-tailed t-test (*p < 0.05).
www.nature.com/scientificreports/
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α DEC-205/OVA immunized mice, we detected antigen-specific CD4+ T cells. While previous studies described 
a preferential induction of Th1 responses by α DEC-205/antigen immunization16,23, we observed similar levels of 
Th1 (IFNγ +) and Th2 (IL-4+) CD4+ T cells (Fig. 2A and B), consistent with minor differences in the IgG sub-
classes (Fig. 1C). Irrespectively of the antibody subclasses, we demonstrate that in comparison to the other for-
mulations the two DC targeting approaches were most effective at inducing a rapid and robust humoral immune 
response (Fig. 1).
While in our hands both DC targeting approaches next to CTL responses induced a rather balanced Th1/Th2 
profile, immunization with OVA + BPPcysMPEG that does not involve DC targeting failed to induce CTLs and 
resulted in a Th2 dominated cytokine profile (Figs 1C and 2). Interestingly, BPPcysMPEG has been shown to 
induce Th1-type immune responses in the context of allergens and parasite antigens36–38. However, intramuscular 
immunization with hepatitis B surface antigen virus-like particles co-administered with BPPcysMPEG resulted 
in a Th2 dominated response39. Therefore, the adjuvant dose, the route of administration and the intrinsic fea-
tures of the antigen may account for the observed differences in the T helper cell phenotype. While Schulze and 
colleagues proved BPPcysMPEG to be a potent mucosal adjuvant for vaccination against severe acute respiratory 
syndrome coronavirus, the authors focused on the cellular and humoral immune responses, but did not test for 
antiviral activity40. Thus, BPPcysMPEG has not been investigated before regarding its potency to induce antiviral 
immunity. In the absence of DC targeting, i.e. by using the OVA + BPPcysMPEG formulation, we clearly show 
the induction of a Th2-biased CD4+ T cell phenotype, the lack of CTLs and in consequence no antigen-specific 
clearance of virus infected hepatocytes. While previous studies have demonstrated the exceptional potential of 
DEC-205-mediated antigen targeting to elicit adaptive immunity14–18,24 to our knowledge this is the first study 
showing the induction of liver-specific immune reactions. We demonstrate that targeting DEC-205+ DCs resulted 
in a high frequency of local IFNγ +CD44+CD8+ memory T cells (Fig. 3C), which correlate with protection against 
adenovirus challenge in the liver (Fig. 6). One critical point in fighting viral infections is to keep the balance 
between protective immunity and immunopathology, which are both mainly driven by CTLs and often decisive 
for the fate of the infected host41,42. For hepatotropic viruses such as HCV, which is not believed to be directly 
cytopathic, liver damage is attributed to T cell-mediated immunity29 and immunopathology is inevitable for 
sterilizing immunity. On the other hand, a less vigorous CTL response allows for viral persistence, ultimately 
Figure 6. Antigen delivery to DCs induces CTLs that clear virus infected hepatocytes. Mice were 
immunized on days 0, 14 and 28 either with α DEC-205/OVA + Poly(I:C)/CpG, α DEC-205 + Poly(I:C)/CpG, 
BPPcysOVAMPEG or OVA + BPPcysMPEG and infected with AdOVA-GFP-luc or Ad-GFP-luc on day 48. (A) 
Quantification of ALT levels before and after adenovirus challenge. Data represent the mean values (± SEM) 
(n = 5). Statistics: two-way RM Anova (*p < 0.05; ***p < 0.001) or paired, two-tailed t-test comparing values 
from day 0 and 4 within the respective group (#p = 0.019; ##p = 0.0056). (B) Luciferase activity in the liver as a 
measure for killing of infected hepatocytes. Relative light units expressed as mean ± SEM (n = 5). Statistics: one-
way Anova (*p < 0.05; **p ≤ 0.0014).
www.nature.com/scientificreports/
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leading to progressive tissue injury43. Only in the α DEC-205/OVA and BPPcysOVAMPEG group could immu-
nopathology be correlated with antigen-specific viral clearance in the liver (Fig. 6). Regarding the severity of 
hepatitis that occurs as a side effect of pathogen elimination, it is highly conceivable that α DEC-205/OVA and 
BPPcysOVAMPEG immunized mice would have recovered from liver damage. In a published model of fulminant 
hepatic failure, ALT levels peaked at day 4–5 post infection, which was the end-point of the experiments in our 
study, and had almost normalized by day 6 post infection44. However, further studies are needed to evaluate the 
consequences of immune-mediated hepatitis.
In terms of clinical application the use of well tolerated adjuvants is of foremost importance. While a number 
of clinical trials indicated that CpG is sufficiently well tolerated, Poly(I:C) was shown to exhibit severe side effects 
in humans45. Of note, its synthetic derivative, PolyICLC, which has already been successfully used in DEC-205 
targeting trials46–48 exhibits a better resistance to hydrolysis as well as a greater potency to induce IFNγ -secreting 
T cells49 than Poly(I:C) and, most importantly, was proven a safe adjuvant in healthy human volunteers50 and 
in cancer patients51,52. Additional studies are needed to clarify whether α DEC-205/OVA vaccination using 
PolyICLC/CpG as an adjuvant will be as efficient as (or even more efficient than) α DEC-205/OVA + Poly(I:C)/
CpG vaccination in inducing antiviral immunity in the liver. Regarding the TLR2/6 agonist BPPcysMPEG which 
is known to activate cross-priming CD8α + DCs in mice, so far no published data are available for clinical appli-
cations. It has recently been shown that human CD141+ DCs which are thought to represent the functional 
equivalent of mouse CD8α + DCs do express TLR2 and 653. Thus, an interaction of BPPcysOVAMPEG with DCs 
via the TLR2/6 receptors is likely to take place also in humans. Nevertheless, future in vitro studies are needed to 
clarify this issue in more detail.
We observed distinct patterns of CD8+ T cell interaction with virus infected and apoptotic hepatocytes, 
dependent on the vaccine formulation we used (Fig. 5C–E). While significantly fewer CD8+ T cells were in 
intimate contact with virus infected hepatocytes in the α DEC-205/OVA-immunized group, these CD8+ T cells 
appear to be more effective in inducing apoptosis which is in line with the higher expression of IFNγ as a marker 
for their cytotoxic potential. It is well established that CTLs eliminate infected hepatocytes after direct antigen 
recognition on target cells via perforin/granzyme or Fas-mediated killing. However, cytotoxicity in virus infected 
hepatocytes can also be exerted via the non-canonical CTL effector function where CTLs are stimulated by 
cross-presenting liver sinusoidal endothelial cells and secrete TNF after stimulation54. TNF induces cell death 
specifically in infected hepatocytes involving caspase-3 activation following TNFR stimulation. Of note, well 
in line with the observed elevated frequencies of IFNγ +CD44+CD8+ CTL in AdOVA-GFP-luc infected livers of 
α DEC-205/OVA compared to BPPcysOVAMPEG immunized mice, the overall IFNγ and as well TNF expres-
sion levels were by far higher in the α DEC-205/OVA treated group (Supplementary Fig. S3). IFNγ secreted by 
highly abundant IFNγ +CD44+CD8+ CTL may account for elevated TNF expression in hepatic macrophages in 
AdOVA-GFP-luc infected α DEC-205/OVA immunized mice. Alternatively, as shown before by Wohlleber et al.54, 
virus-specific CTLs induced during α DEC-205/OVA may be the source of TNF. While further investigation is 
needed to decipher the specific mechanisms underlying the elimination of virus infected hepatocytes in α DEC-
205/OVA and BPPcysOVAMPEG vaccinated mice, we may speculate that immune surveillance in α DEC-205/
OVA immunized mice in addition to cell-contact dependent CTL-mediated killing to a higher degree involves 
cytokine-mediated effector functions. At first line TNF may be the most important cytokine involved in elim-
ination of virus infected hepatocytes as it can induce apoptosis in adenovirus infected hepatocytes. Although 
IFNγ has been shown to exert non-cytolytic antiviral effector function in HBV infected hepatocytes55, previous 
reports have shown that IFNγ ko mice behave exactly the same as wildtype mice with regards to antiviral immune 
response against adenovirus infected hepatocytes and following liver damage28,54. This does not exclude that high 
levels of IFNγ may enhance secondary antiviral effects for example by the upregulation of antigen-presentation 
by hepatocytes enhancing recognition of infected cells by CTLs.
The induction of antiviral immunity in the liver is per se a challenging issue. A hallmark of e.g. HCV persis-
tence is the appearance of functionally impaired and exhausted T cells that are unable to secrete antiviral effector 
molecules, show impaired proliferation29,56,57 and dysregulate expression of activating/inhibitory receptors58–60. 
Next to this, in patients chronically infected with HCV the higher frequency of suppressive CD4+CD25+ T regu-
latory cells61 most likely contribute to T cell dysfunction. Since blocking of PD-1, CTLA-4 and Tim-3 hold some 
therapeutic promise for the functional recovery of exhausted T cells59,60,62, a combined strategy encompassing 
both antibody-mediated blocking of immunosuppressive pathways together with boosting antiviral immunity 
by means of DEC-205- or TLR-mediated antigen delivery to cross-presenting DCs could represent a promising 
scenario for future developments. This may also imply the use of DC targeting as a therapeutic vaccine, which 
has been shown to be clearly effective in several other studies14,21,25, and might also contribute to the treatment of 
patients with hepatic virus infection after liver transplantation to avoid reinfection.
Methods
Mice. Female C57BL/6 mice were obtained from Harlan Winkelmann (Borchen, Germany) and housed 
under specific pathogen-free conditions according to the national and institutional guidelines. All experiments 
were approved by the local government agency (Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit; file number 33.12-42502-04-10/0108) and have been performed in accordance to these 
guidelines.
Antibodies, antigens and cell lines. EndoGrade OVA was obtained from Hyglos (Germany). OVA pep-
tides CD4323–339 (ISQAVHAAHAEINEAGR) and CD8257–264 (SIINFEKL) were synthesized at the Helmholtz 
Centre for Infection Research (Germany). The DEC-205 antibody was purified from NLDC-14563 hybridoma 
supernatant by affinity chromatography.
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Conjugation of OVA to αDEC-205. Chemical conjugation of purified α DEC-205 to OVA was performed as pre-
viously published64 with minor modifications. In brief, α DEC-205 was first activated by sulfo-SMCC (sulfosuccinimidyl 
4-[N-maleimidomethyl] cyclohexane-1-carboxylate) (Thermo Fisher Scientific, USA), according to the manufacturer’s 
protocol, and in parallel the sulfhydryl-groups of the OVA protein were exposed by using 30 mM tris(2-carboxyethyl)
phosphine hydrochloride (TCEP-HCl) (Thermo Fisher Scientific, USA) (1.5 hours at room temperature). Excess of 
TCEP and sulfo-SMCC in the respective samples was removed using Zeba Desalt Spin Columns, according to the 
manufacturer’s recommendations (Thermo Fisher Scientific, USA). The reduced OVA was immediately mixed with the 
activated antibody and incubated overnight at 4 °C. The resulting α DEC-205/OVA conjugate was concentrated and sep-
arated from unbound OVA using 150 K MWCO Pierce® concentrators (Thermo Fisher Scientific, USA). Quantification 
of the OVA content within the α DEC-205/OVA conjugate was achieved by comparison of OVA signal intensities on 
Western blot with graded quantities of OVA on the same blot (Supplementary Fig. S4)14. Quantitative proportions of 
OVA peptide epitopes contained in the α DEC-205/OVA, BPPcysOVAMPEG and OVA + BPPcysMPEG vaccine for-
mulations calculated on the basis of molar mass were determined as 1:7 (α DEC-205/OVA:BPPcysOVAMPEG), 1:12.5 
(OVA + BPPcysMPEG:BPPcysOVAMPEG) and 1:1.7 (OVA + BPPcysMPEG:α DEC-205/OVA).
TLR ligands. Poly(I:C) and CpG were purchased from Invivogen (Germany) and Eurofins MWG Operon 
(Germany), respectively. BPPcysMPEG (International Patent Classification: A61K47/48(2006.01), Pub. No.: 
WO/2007/059931) and BPPcysOVAMPEG (PCT/EP 09016050.8) were synthesized at the Helmholtz Centre for 
Infection Research (Germany).
Immunization. Mice were subcutaneously immunized on days 0, 14 and 28 with either 30 μ g α DEC-205/
OVA, 30 μ g α DEC-205, 10 μ g BPPcysOVAMPEG12 or 7 μ g OVA co-administered either with 50 μ g Poly(I:C) and 
50 μ g CpG, as previously published15,16,24,25 or 5–10 μ g BPPcysMPEG39 in a total volume of 50 μ l PBS per animal.
Determination of serum ALT. For ALT quantification, 75 μ l peripheral blood were mixed with 25 μ l 1% hep-
arin (Ratiopharm, Germany), centrifuged (10,600× g, 10 minutes, room temperature) and 32 μ l of the supernatant 
were used for detecting ALT activity using the scil Reflovet® Plus reflection-photometer (scil animal care, Germany).
Analysis of liver lymphocytes. Livers were perfused with ice-cold PBS and minced on ice followed by enzy-
matic digestion in IMDM (Gibco, Germany) containing 0.2 mg/ml collagenase D (Roche, Germany), 10 μ g/ml 
DNase (Sigma, Germany) and 5% FCS for 30 minutes at 37 °C. After addition of EDTA (5 mM final concentra-
tion), cells were pelleted by centrifugation (15 minutes at 300× g) and liver lymphocytes were enriched by Percoll 
density gradient centrifugation. The cells were stimulated with a mixture of OVA protein and the OVA peptides 
CD4323–339 and CD8257–264 (20 μ g/ml final concentration for all) for 24 hours at 37 °C. The cells were then stim-
ulated by incubation with 0.01 μ g/ml PMA (Sigma, Germany) and 1 μ g/ml ionomycin (Sigma, Germany) for a 
total of 4 hours, 10 μ g/ml Brefeldin A (Sigma, Germany) were added after 2 hours. For flow cytometric analysis, 
Fc-block was performed through incubation with anti-mouse CD16/CD36 antibody (2.4G2) followed by surface 
staining for mouse CD8 (53–6.7) and CD44 (IM7) (BD Biosciences, eBioscience). After fixation (2% paraform-
aldehyde/PBS v/v), cells were permeabilized using 0.1% Igepal® CA-630/PBS (Sigma, Germany) and stained for 
intracellular IFNγ (XMG1.2). Data were acquired on an LSR Fortessa instrument (BD Biosciences) and further 
analysed using the FlowJo software (Tree Star, USA).
Detection of antigen-specific serum IgG. To monitor the humoral immune response, 75 μ l of blood were 
collected from the retro-orbital sinus and serum was obtained through incubation of the samples for 45 minutes 
at 37 °C, followed by 45 minutes incubation at 4 °C and subsequent centrifugation (10 minutes at 420× g). Sera 
were assayed for the presence of antigen-specific IgG and IgG subclasses (IgG1, IgG2c) by enzyme-linked immu-
nosorbent assay (ELISA) using 96-well Nunc-Immuno MaxiSorp plates (Nunc, Germany) coated with 2 μ g/ml 
OVA protein in 0.05 M carbonate buffer (pH 9.6). After overnight incubation at 4 °C, the plates were washed 
with PBS supplemented with 0.1% Tween 20 and blocked with 3% BSA in PBS for 1 hour at 37 °C. Serial 2-fold 
dilutions of sera in 3% BSA/PBS were added and plates were further incubated for 2 hours at 37 °C. After washing, 
antibody binding was detected using biotin-conjugated goat α -mouse IgG (Sigma, Germany), goat α -mouse IgG1 
(Southern Biotech, USA) and goat α -mouse IgG2c (Southern Biotech, USA) antibodies (1 hour, 37 °C), respec-
tively, and streptavidin-HRPO (BD Biosciences, Germany) (30 minutes, 37 °C). ABTS in 0.1 M citrate-phosphate 
buffer (pH 4.35) containing 0.03% H2O2 was added to each well and the absorbance at 405 nm was recorded after 
30 minutes of incubation. Endpoint titres were expressed as the reciprocal value of the last serum dilution which 
yielded an absorbance two times above the values of negative controls.
Enzyme-linked immunosorbent spot (ELIsPOT) assay. ELISPOT kits for the detection of murine 
IFNγ (eBioscience, Germany) and IL-4 (BD Biosciences, Germany) were used according to the manufacturer’s 
instructions. Spots were counted with an ELISPOT reader (C.T.L. Europe GmbH, Germany) and analysed using 
the ImmunoSpot image analyser software v3.2 (C.T.L. Europe GmbH, Germany). The results are presented as spot 
forming units per 106 cells.
In vivo cytotoxicity assay. Splenocytes were isolated from naive syngeneic donor mice and equal cell 
numbers were pulsed with 1 μ g/ml SIINFEKL (OVA257–264) peptide for 30 minutes at room temperature or left 
untreated followed by labelling with 2.5 μ M (CFSEhigh) or 0.25 μ M (CFSElow) CFSE, respectively, and mixing in a 
one to one ratio. A total of 2 × 107 target cells was intravenously (i.v.) injected into recipient mice. After one day, 
splenocytes were re-isolated and the ratio of CFSEhigh to CFSElow labelled cells was determined by flow cytometry 
using a FACS Canto instrument (BD Biosciences, Germany).
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Adenovirus challenge assay. On day 42 after the first immunization, mice were infected intravenously 
with 2 × 108 plaque forming units (PFU) of a recombinant adenovirus expressing fusion proteins either of GFP 
and luciferase (Ad-GFP-luc) or GFP, luciferase and the OVAaa257–264 SIINFEKL (AdOVA-GFP-luc). Control ani-
mals received PBS and were either mock-infected (PBS) or infected with AdOVA-GFP-luc28. For luciferase activity 
assays, the lower liver lobe was separated into two parts, weighed and tissue fragments were homogenized in 
proportional volumes of reporter lysis buffer (Promega, Germany) using Lysing Matrix D (MP Biomedicals, 
Germany) and a FastPrep-24 instrument (3 × 10 sec, 5.5 m/sec). After centrifugation (3 minutes, 10,000× g, 
4 °C), lysates were mixed with Luciferase Assay Reagent II (Promega, Germany) and measured in a luminometer 
(Berthold Technologies, Germany).
MELC analyses. Liver tissues of α DEC-205/OVA + Poly(I:C)/CpG and BPPcysOVAMPEG immunized 
mice were snap frozen and embedded into O.C.T. (Sakura Finetek). Liver samples from α DEC-205/OVA and 
BPPcysOVAMPEG mice displaying comparable ALT levels were in each case analysed by the MELC robot in 
parallel. Cryosections of 10 μ m thickness, which adhere to silan-coated cover slides, were prepared on Leica 
Cryostat CM3050, fixed with 2% paraformaldehyde (Santa Cruz) and permeabilized with 0.2% Triton-X-100 
before blocking with 1% BSA/PBS (Sigma) for 1 h. Detailed information on image acquisition and analysis are 
described in the Supplementary material. Optimal antibody dilutions, incubation times, and positions within 
the MELC experiment for all antibodies used (see Supplementary Table S1) were validated systematically using 
conditions suitable to MELC65 (see Supplementary Figure S5).
Histological analyses. The left upper liver lobe was fixed in 4% formaldehyde solution, followed by paraf-
fin embedding, preparation of 2–4 μ m sections and staining with haematoxylin and eosin (H&E). Histological 
evaluation was performed by an animal pathologist certified by the American College of Veterinary Pathologists 
in a blinded fashion.
Statistical analyses. Results were statistically analysed by one-way Anova followed by the Dunnett’s test, 
two-way RM Anova, non-parametric Mann Whitney test or the paired, two-tailed t-test using the Graph Pad 
Prism 5 software (Graph Pad software, La Jolla). Data are presented as mean ± SEM or mean ± SD and a p-value 
below 0.05 was considered significant.
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